Lilly Alimta $3,900 Per Course Of Therapy, Available In Two Weeks
Executive Summary
Lilly plans to launch the malignant pleural mesothelioma agent Alimta at a net price of $3,900 per course of therapy
You may also be interested in...
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Lilly Alimta For Lung Cancer “Reasonably Likely” To Improve Survival
Lilly's Alimta is "reasonably likely" to improve survival in non-small cell lung cancer patients despite not meeting the primary endpoint of overall survival in pivotal trials, labeling says
Lilly Alimta Lung Cancer Use Supported By FDA Cmte.; Safety Profile Cited
The favorable toxicity profile of Lilly's oncologic Alimta outweighs uncertain survival benefits in the second-line treatment of non-small cell lung cancer, FDA's Oncologic Drugs Advisory Committee agreed July 27